Organon & Co
Prix: 13.44Entreprise et modèle économique
Organon & Co is a global healthcare company focused on women's health, biosimilars, and established medicines. Its core products include contraceptives, hormone therapies, and treatments for various chronic conditions. The company operates primarily in women's health and biosimilars, with major revenue sources stemming from its portfolio of prescription medications and healthcare solutions. Organon aims to address unmet medical needs and improve health outcomes for women.
Profil d’investissement
The investment profile of Organon & Co is more aligned with balanced investors, given its modest dividend yield and stable revenue streams. The company has shown some volatility and a recent decline in revenue, which may appeal to those seeking a mix of growth and income. The stock's characteristics suggest it may be suitable for investors looking for moderate risk and potential for steady returns over time.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 0.95 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -3.1% ↓
- Surprise BPA
- -14.5% moins bon que prévu
- Volatilité 20 j
- 0.2% stable
- Rendement du dividende
- 0.6% faible dernière date ex-dividende: 2026-05-11
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-13 02:43 | Conserver | Vendre | Weak fundamentals and mixed momentum signal caution. |
| 2026-06-05 02:45 | Vendre | Conserver | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-28 02:54 | Conserver | Vendre | Weak fundamentals and negative momentum raise concerns. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-04-27 20:27 | Piper Sandler | Note relevée | — → 14 | 13.175 |
| 2026-04-10 15:02 | BNP Paribas | Mettre à jour | — → 12 | 8.685 |
| 2026-02-24 10:45 | Barclays | Objectif relevé | 7.5 → 8 | 7.92 |
Rien pour le moment